Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes.....very good news!!!
Attn all.......this seems too good to be true.
Just called the TA.
The past 2 full trading days have had no dilution.
O/S has NOT changed since my last call.
319,279,241
tomorrow is the day when you will be able to see Jan 31 data.
It's hard to have high morale when you initially invest here on the premise the heart results will bring great notoriety to ENDV and cause the SP to rocket up and here we are....sitting at or below the initial investment value.
I also believe the overall stock market dip had demoralized quite a few. Why get excited on a tiny green day.
I'm still keeping faith in the company and technology.
The company has certainly started the new year better than last year.
We had acquisition news, human clinicals to commence this year, confirmation and more data release of positive heart results, an attempt to fight and understand the short selling and/or manipulation, and increased communication.
Yes, seems to be 4 days in a row now with no T Trade. I have not tracked this before. Not sure what is our longest span with no T trade under the dilutive financing.
I don't have the tools to research this at the moment.
I sure hope it means we have something in the works in regards to better financing.
Maybe we get a PR this week. We have been getting a PR weekly lately. Let's hope the trend continues.
Thanks for sharing.
Then we need an IR firm to get us to that 5m to test your theory.
ENDV certainly did try recently. Not sure who was with the idea behind this attempt.
Jan 31, ENDV tweeting the story of 4 BIO stocks to watch in 2018.
Jan 31, a poster pumping ENDV on 2 I-Hub forum boards outside of ENDV's forum to attract interest.
Feb 1, a different pumper posting numerous messages on ENDV's forum to get us on the breakout board top 10 (we made it to #2).
Feb 1, AM PR, Tweet, and FB post of the heart results.
All of that and we only got 2.7m volume.
The last time we had over 5m vol. was in Oct. for the positive results PR.
Amazing with all the extra effort that was made this time, only half of the Oct. volume was achieved.
I think the Sept. and Oct. PRs were the main surprises of the heart results.
Maybe a successful PR of the ischemia pre-clinical can be a catalyst. That would make 2 successful pre-clinicals in a row.
I looked at the financials of the manufacturer of Sofpulse.
"The decrease in the engineering division is primarily the result of decreased sales volume from one customer".
The 6 month engineering revenue was $760k and the 1 customer was 57% of that figure...$433k.
I will make the assumption the declining customer was RGN (Rio Grande) with Sofpulse. I know the customer could also be Assisi loop for the pets, but I'll also assume they were a smaller customer % (and RGN was getting a licensing fee from it).
If the cost to RGN was $433k, they would have resold for maybe 75% higher? That would be $325k profit.
Let's say ENDV gets reorders for the same amount in the first 6 months while they figure out their own sales channels and licensing deals. The $325k would keep dilution at bay for close to only 1 month.
The current dilution is about $400k monthly (8m shares x $.05).
This is my first stab at looking at revenue possibility for ENDV. I don't need to be correct. Anyone can chime in and add if so desired. Without knowing RGN's financials nor how many units are being sold by ADM, this is my "guesstimate".
It appears we now have 3 days in a row without a T trade.
Any word on shareholder meeting/dinner?
The shares are being diluted. Seems the company needs money or a toxic noteholder is selling shares. Need VNDM to disappear.
I can see the sudden explosion of volume on the stock trading history. It seems the volume also trended much higher than average during those 3 weeks.
What is strange is the 25m volume occurred on March 13, but I don't see any ENDV PR around that time. First PR I see is March 23 about the patent.
Prior to that was in December about the heart pre-clinical commencing and had an estimated time of completion end of Q1.
Seems the volume was pouring in solely on the anticipation of the heart results.
We get great results now and can't even get close to that volume now.
Yesterday, one of the famous R/S and diluting shipping companies had 69m volume compared to the 9m they were averaging. The stock only closed up slightly green at the end of the day.
Everyone thought the short squeeze was going to happen and it never did.
Holy mother of shorting!!!!!!
I am no expert of shorting and don't claim this to be 100% accurate, but if it is....Houston....we have a problem!!!!
I found this article online.
https://www.google.com/amp/s/mrtopstep.com/stop-abusive-and-illegal-short-selling/amp/
Within that article is a link to view the short selling statistics.
http://regsho.finra.org/regsho-Index.html
I looked up ENDV and found this data for the past 3 trading days.
2/1 - 1,071,012 short / 2,539,963 vol.
42% short vol
2/2 - 486,718 short / 699,346 vol.
70% short volume
2/5 - 608,859 short / 1,590,438 vol
38% short volume
Nasdaq Regulation SHO list reports how many shares were initiated as a short on a daily basis. If you are seeing more than 20% of overall volume initiated short on a daily basis you are probably under an abusive/illegal shorting attack. Here is the link: http://regsho.finra.org/regsho-Index.html. Click on the day and scroll down to your ticker symbol. The 1st set of numbers is the shares the were initiated as a short, and the second set of numbers is the volume for the day. Make sure you click on the market that your stock trades on. (Nasdaq listings the 1st set, NYSE the 2nd set and the 3rd set is the OTC and pinks).
I believe Brojazzy says this site is not accurate but only another site that reports every 2 weeks is?
Can anyone provide more info why this daily site is not accurate?
Is this company referencing the daily site to instill fear into prospective clients?
If so, how can you trust a company if they are relying on bad data?
Let's hear feedback from someone with more knowledge about shorting and these stats.
We should be concerned about some revenue. Otherwise the dilution continues to wear us down.
I am concerned why the heart failure was not listed as a bullet point in the "2018 expected milestones".
2018 expected milestones:
- brain injury clinical
- concussion clinicals
- MS study
- licensing agreements
- uplist
I understand they got the results in 2017 but why is there no mention of human heart clinical trial in 2018?
Is there going to be continuous follow-up on additional findings and then a pause for feedback from the scientific community?
Share structure update.
O/S count this AM is 319,279,241.
From my last call on Jan 19, this represents an average weekly dilution rate of 1.1m. This is the smallest average that I have seen since tracking it.
The daily avg for the past 2 weeks (and couple of days) is 227.5k.
I suppose the last 2 days of no T trades helped. Let's see if that trend continues.
I am sure they are. The question is when can they really secure that financing?
You watch Shark Tank? You see how often they are hesitant to invest in a person that is pre revenue? They get excited with revenue numbers and proven sales.
I think the same applies here with Endonovo.
I don't believe ENDV will have much in the way of revenue this quarter. They are working on the distribution and sales channels.
Will that be enough for acquiring better financing or are we going to have to wait at least for 2Q results to see some fruits of the labor?
Maybe Endonovo can use the Chronic Traumatic Encephalopathy (CTE) angle for the HDE designation.
CTE was usually diagnosed after death. Only recently have they have found a way to see CTE on a living person and the stats are low at the moment.
There are many more people diagnosed with PCS than 4k yearly.
From my Google searching......
There are 4 million people diagnosed with concussions yearly. The rate of PCS of those concussed people ranges from 10% - 13%. That would be 400k people with PCS.
Forget NASDAQ for the moment.
What is it going to take for us to even get to $0.50?
Do you think the initiation of human clinicals on the concussion studies can do it?
Do you see ENDV starting human trials on the heart during the same time as concussion trials?
Can ENDV afford to run multiple human clinicals at the same time? (Concussion, heart, MS, maybe Ischemia)
Is it going to take the heart data to be published in a scientific journal to get ENDV noticed?
We are not going to know anything about revenues from Sofpulse sales until 1st Q ER in May. We can't count on revenue support for some time.
Maybe ENDV can prove abuse of power or illegal trading practice from the MMs?
Maybe our next PR will have this as the title:
Endonovo Therapeutics Is Working With a Long-Term Company Investor to Redeem and Restructure the Remaining Convertible Notes on Better Terms in an Ongoing Effort to Protect Shareholder Value
Don't we wish!!!!!
Everyone, go outside tonight and make that a wish on a shooting star.
Looks like management tried the "paid pumper" route for the last PR. Did not seem to do much. Volume increased to 200m and yet we barely closed green.
Concussion story on Yahoo today.
https://www.yahoo.com/sports/nfl-players-wife-details-football-destroyed-husbands-mind-220418905.html
In this article, it is stated NFL made a billion-dollar concussion settlement with players some time ago. NFL had disregarded connections between football and traumatic brain injuries for quite some time. Now they are on the wagon of research. NFL has deep pockets and big PR potential.
Hopefully Endonovo does not take too long to redesign the assets from RGN. We need to strike while the iron is hot.
Let's get those human clinical concussion trials started.
What are we to expect as the next catalyst from ENDV?
The recent heart news has provided further need to a follow-up study needed before human trials.
The tPEMF products acquired from RGN are being redesigned. Who knows how long this will take before they complete this and will be ready for the human clinicals.
Hopefully we will hear something about the ShareIntel analysis and the MM manipulation that is happening with the stock. The MMs would not be able to manipulate this stock as well, if we were to maintain with mostly "long" position holders. I do believe we have this, but unfortunately we have the dilution adding more shares and keeping us longs from holding the advantage. If we keep the shares locked up, it keeps the MMs short and having no choice but to cover.
So, that brings me to the next catalyst we NEED to see: Financing
If ENDV can eliminate this toxic debt and dilution, the MMs will not be able to manipulate this stock as well. We do have a lot of long holders here. We are suffering at the hands of the dilution.
Revenue can assist with eliminating the dilution. If ENDV can sustain themselves with revenue, no need for toxic financing. Since there are many clinicals still needing to be performed before we can count on revenue for those devices, the only source of revenue will be the sales of Sofpulse. We need to see this get ramped up and soon.
It seems there needs to be a media blitz. Advertise. Not only salespeople knocking on doors. Get the word out via more channels of marketing. If there is CMS coverage for Endonovo's device, how can more people/doctors get to know about it?
The Sofpulse seems to be marketed more heavily towards plastic surgeries. Advertise in a media format that will grab the attention of future patients and current doctors.
Let's get the revenue rolling in to help support the operations and the elimination of the toxic notes!!
A strategic investor would help also, but it does not seem apparent ENDV is eager to give up much % of the company for that purpose.
The O/S maxing out and R/S delay is an ideal situation.
BUT, the power to raise A/S is something else that could derail any rally.
Have not kept up with the posts here.
Has there been any commitment by ICLD to NOT raise A/S again?
What are you thoughts on the new details just released of the heart study? Anything new catch your attention?
Spread the word to your scientific buddies. We could use the support of people "in the know" of this research and not just stock investors.
We are in a battle against the manipulating/shorting market makers keeping the stock price so low.
I believe the doctors need to order on behalf of the patient.
IR emails to Steve....
Let's give them some time to digest the emails and produce an overall PR to shareholders.
We have been getting a communication basically every week now since the acquisition. With the quantity of emails they may have received or will be receiving can create the need for a PR.
Thumbs up to those that sent or will send emails to IR.
You are using PEMF device for sinuses?
Tell me more. Have a relative that suffers all the time from sinus issues (mostly allergies I believe). Has tried numerous types of treatments.
I went to the Sofpulse website.
Seems to be 1 device, 1 shape?
Does not appear to be the type of device for wound healing.
It is more for pain and inflammation.
I'm trying to get a better understanding of how someone can use PEMF for wound healing under CMS.
If it's the Sofpulse, how are they treating the wound on the arm (for example) if it's a big looped ring like the Sofpulse?
Did the companies you lost with, that had the R/S, have toxic debt (continued dilution) during the time of R/S?
Where did we end up on the Breakout Board today? Can't see from phone app.
That settles it.
Email campaign to Endonovo.
Name, ticker symbol, CUISP # changes needed.
No R/S unless the toxic debt is eliminated.
Change name from Endonovo Therapeutics to Endonovo Electroceuticals.
Problem solved and name better reflects the business.
It is VERY bad when the company has toxic debt. Eliminate the toxic debt, then a R/S will not be so bad.
Endonovo should make a slight change of their corporate name. That would be the ideal situation. Let's not even mention reverse split while there is dilution.
The name change would require new CUSIP#. THEN the MMs will be required to account for each of the old shares with the new shares.
On a positive note, ENDV has released a PR in each of the last 4 weeks.
The commitment to shareholder communication is holding up so far.
They key is to know how many shares short and what will it take to make them cover? (How many shares on the Ask).
Biotech once posted he thought there would be a short squeeze one day earlier this month and it never happened.
He was basing his analysis on a daily short report.
Is that daily short report website really accurate?
I have heard the only true accurate short report is the one that is posted bi-monthly.
I have never analyzed those short reports and/or websites. Sometime I think the unknowns are just blamed on shorting.
Guess it's time to really look into this.
Send an email to ENDV IR (Steve Barnes). Ask about a ShareIntel update.
If enough of us write an email about the same topic, maybe they release a communication / update about it.
Appears so. See the traditional 10k transactions during that drop.